Abstract:Objective to investigate the clinical effect and safety of percutaneous transhepatic portal vein stent placement(PTPVS) combined with transcatheter arterial chemoembolization(TACE) for the treatment of hepatocellular carcinoma(HCC) complicated by tumor thrombus in portal vein,and to discuss the possible factors affecting the prognosis.Methods According to the inclusion criteria and exclusion criteria,62 patients with clinically-confirmed HCC associated with portal vein tumor thrombus,who were encountered during the period from January 2009 to October 2010 in authors' hospital,were enrolled in this prospective two-arm nonrandomized trail.These patients were randomly divided into study group(n = 32) and control group(n = 30).Simple TACE(THP 40 mg/m2,Oxaliplatin 135 mg/m2,mitomycin C 6 mg/m2,lipiodol 5-20 ml) was used in patients of control group,while PTPVS with subsequent TACE was employed in patients of study group.PTPVS failed in two patients of study group.The overall survival time and the safety were used as the evaluation indexes.All patients were followed up.The procedure-related complications occurred after PTPVS were recorded.A data base on clinical information and follow-up outcome of all patients was set up and SPSS13.0 was used for statistical analysis.Median survival time and survival curve of the patients were analyzed by Kaplan-Meier method.A log-rank analysis was performed to identify group differences.Cox's proportional hazards model was used to analyze the variables affecting the patients' prognosis.Results The median overall survival time of the study group was 6.5 months,while the median overall survival time of the control group was 4.5 months(hazard ratio in the study group: 0.57,95%,confidence interval: 0.328-0.992,P = 0.037).Significant difference in the median overall survival time existed between the two groups.The cumulative survival rates at 3,6,12 and 18 months in the study group were 70%,56.7%,10% and 3.3%,respectively.In the study group,no procedure-related complications occurred within 1 week after the operation.The long-term complications in the study group included hepatic encephalopathy(n = 2,6.6%),upper gastrointestinal hemorrhage such as hematemesis and melen(n = 3,10%) and hepatorenal syndrome(n = 1,3.3%).Conclusion For the treatment of patients with HCC complicated by partial obstruction of the main trunk or the rst-order branch of the portal vein due to tumor thrombus,PTPVS combined with TACE is safe and effective.this combination therapy can improve The median survival time of patients receiving this combination therapy is about two months longer than that of patients receiving TACE alone.

Treatment of Hepatocellular Carcinoma-associated Portal Vein Tumor Thrombus Using Combination of Portal Vein Stent Insertion and Endovascular Lodine-125 Seed-strip Implantation Followed by Transcatheter Arterial Chemoembolization- Sorafenib

A combination of portal vein stent insertion and endovascular iodine-125 seed-strip implantation, followed by transcatheter arterial chemoembolization with sorafenib for treatment of hepatocellular carcinoma-associated portal vein tumor thrombus

Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis

Portal Vein Stenting Combined 125I Particle Implanted Followed by Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Irradiation stent with <SUP>125</SUP>I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs.125Iodine Implantation

Combined Endovascular Brachytherapy, Sorafenib, and Transarterial Chemobolization Therapy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.

Efficacy of Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Portal Vein Stent Placement Combined with TACE for the Treatment of Hepatocellular Carcinoma Associated with Tumor Thrombus in Portal Vein

Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed.

Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Preliminary Results of Main Portal Vein Tumor Thrombus Treated by Endovascular Brachytherapy Combined with Sorafenib

Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine-125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus]

[Endovascular placement of iodine-125 seed strand and self-expandable stent combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with tumor thrombus in the main portal vein].

Radomized comparative study of hepatocellular carcinoma with extensive portal vein tumor thrombus treated by TACE combined with or without endovascular implantation of iodine-125 seeds strand

Randomized comparative study of HCC with MPVTT treated by portal vein stent and TACE combined with or without

Efficacy and Safety of Endovascular Brachytherapy Combined with Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma Patients with Type III or IV Portal Vein Tumor Thrombosis

Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas

TACE Combined with Portal Vein Tumor Thrombus 125I Seed Implantation in the Treatment of HCC with Hepatic Arterioportal Shunts